lilly

Transcriptic announced today that it has entered into a multi-year collaboration agreement with Eli Lilly and Company whereby Lilly will license the Transcriptic Common Lab Environment (TCLE) to enable on-demand drug discovery operations at its San Diego Biotechnology Center. The solution Transcriptic is developing for Lilly will allow researchers across the globe to remotely design, synthesize and screen investigational molecules at the Lilly Life Science Studio (L2S2).

Headquartered in Silicon Valley, Transcriptic created the first robotic cloud laboratory platform for on-demand life science research. The company’s TCLE integrates laboratory processes, protocols and instruments together with IoT technologies through a single user interface to enable robust automation, scalability, flexibility and remote instrument monitoring.

Using the power of automation along with artificial intelligence and machine learning, Transcriptic and Lilly will seek to shape the next generation of drug discovery and expand the reach of individual scientists to test new ideas, while reducing the cost, accelerating the speed and minimizing the environmental impact of research activities.

Bret Huff, Lilly’s Vice President of Small Molecule Design and Development said:

“We are excited to extend the Transcriptic TCLE environment to our San Diego Biotechnology Centre. We believe this capability will transform how new drugs are discovered internally and enhance Lilly’s partnerships with external innovators.”

Yvonne Linney PhD, Transcriptic’s Chief Executive Officer commented:

“We were impressed with the forward-thinking investment Lilly made in its Life Science Studio and are excited that the global pharmaceutical leader chose Transcriptic to power the L2S2 through our platform. Our mutual goal is to revolutionize drug discovery and find ways to accelerate the process and increase success. We are confident that the Transcriptic Common Lab Environment is the right technology platform to support the next wave of innovation in biotechnology.”

Matt Ocko, Managing Partner of DCVC (Data Collective) said:

“We became early, major investors in Transcriptic because we felt strongly that leaders in the pharmaceutical industry would demand a landmark shift in how science drives drug discovery, and that artificial intelligence and robotics would be key to this industry transformation. The Lilly – Transcriptic partnership validates DCVC’s fundamental investment thesis in the life sciences.”

Follow @transcriptic to stay informed about their latest news and more.